{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:18:04Z","timestamp":1785860284641,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Valtion tutkimusrahoitus"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00280-021-04236-y","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T06:26:30Z","timestamp":1612506390000},"page":"657-663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population"],"prefix":"10.1007","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2580-2830","authenticated-orcid":false,"given":"Jatta","family":"Saarenheimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesna","family":"Wahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalja","family":"Eigeliene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravichandra","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gajja S.","family":"Salomons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde Fernandez","family":"Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymon","family":"Vijzelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Jekunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 B. P.","family":"van Kuilenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"4236_CR1","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJMra040958","volume":"352","author":"JA Meyerhardt","year":"2005","unstructured":"Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476\u2013487","journal-title":"N Engl J Med"},{"key":"4236_CR2","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1056\/NEJMoa043116","volume":"352","author":"C Twelves","year":"2005","unstructured":"Twelves C, Wong A, Nowacki MP, Abt M, Burris H III, Carrato A et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696\u20132704","journal-title":"N Engl J Med"},{"key":"4236_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2019.09.028","volume":"124","author":"C Barin-Le Guellec","year":"2020","unstructured":"Barin-Le Guellec C, Lafay-Chebassier C, Ingrand I, Tournamille JF, Boudet A, Lanoue MC et al (2020) Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real\u2013life evaluation in France. Eur J Cancer 124:37\u201346","journal-title":"Eur J Cancer"},{"key":"4236_CR4","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","volume":"16","author":"E L\u00e9vy","year":"1998","unstructured":"L\u00e9vy E, Piedbois P, Buyse M, Pignon JP, Rougier P, Ryan L et al (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16:3537\u20133541","journal-title":"J Clin Oncol"},{"key":"4236_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1023\/A:1006416410198","volume":"18","author":"JL Grem","year":"2000","unstructured":"Grem JL (2000) 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 18:299\u2013313","journal-title":"Invest New Drugs"},{"issue":"10","key":"4236_CR6","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1200\/JCO.2005.02.167","volume":"23","author":"E Bajetta","year":"2005","unstructured":"Bajetta E, Procopio G, Celio G, Gattinoni L, Della Torre S, Bajetta LM et al (2005) Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 23(10):2155\u20132160. https:\/\/doi.org\/10.1200\/JCO.2005.02.167","journal-title":"J Clin Oncol"},{"key":"4236_CR7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","volume":"40","author":"ABP Van Kuilenburg","year":"2004","unstructured":"Van Kuilenburg ABP (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5\u2013fluorouracil. Eur J Cancer 40:939\u2013950","journal-title":"Eur J Cancer"},{"key":"4236_CR8","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2217\/pgs.11.72","volume":"12","author":"U Amstutz","year":"2011","unstructured":"Amstutz U, Froehlich TK, Largiader CR (2011) Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12:1321\u20131336","journal-title":"Pharmacogenomics"},{"key":"4236_CR9","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1002\/ijc.29654","volume":"137","author":"G Toffoli","year":"2015","unstructured":"Toffoli G, Giodini L, Buonadonna A, Berretta M, De Paoli A, Scalone S et al (2015) Clinical validity of a DPY-based pharmacogenetics test to predict severe toxicity to fluoropyrimidines. Int J Cancer 137:2971\u20132980","journal-title":"Int J Cancer"},{"key":"4236_CR10","first-page":"5433","volume":"53","author":"Z Lu","year":"1993","unstructured":"Lu Z, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433\u20135438","journal-title":"Cancer Res"},{"key":"4236_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0065-2571(00)00011-X","volume":"41","author":"MR Johnson","year":"2001","unstructured":"Johnson MR, Diasio RB (2001) Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 41:151\u2013157","journal-title":"Adv Enzyme Regul"},{"key":"4236_CR12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/cpt.531","volume":"101","author":"T Elraiyah","year":"2017","unstructured":"Elraiyah T, Jerde CR, Shrestha S, Wu R, Nie Q, Giama NH et al (2017) Novel deleterious dihydropyrimidine dehydrogenase variants may contribute to 5-fluorouracil sensitivity in an East African population. Clin Pharmacol Ther 101:382\u2013390","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"4236_CR13","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1038\/bjc.2013.262","volume":"108","author":"A Loganayagam","year":"2013","unstructured":"Loganayagam A, Hernandez MA, Corrigan A, Fairbanks L, Lewis CM, Harper P et al (2013) Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 108(12):2505\u20132515. https:\/\/doi.org\/10.1038\/bjc.2013.262","journal-title":"Br J Cancer"},{"key":"4236_CR14","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","volume":"5","author":"A Morel","year":"2006","unstructured":"Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, Gamelin E (2006) Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 5:2895\u20132904","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"4236_CR15","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","volume":"16","author":"D Meulendijks","year":"2015","unstructured":"Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U et al (2015) Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16(16):1639\u20131650. https:\/\/doi.org\/10.1016\/S1470-2045(15)00286-7","journal-title":"Lancet Oncol"},{"issue":"3","key":"4236_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","volume":"34","author":"MJ Deenen","year":"2016","unstructured":"Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H et al (2016) Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 34(3):227\u2013234. https:\/\/doi.org\/10.1200\/JCO.2015.63.1325","journal-title":"J Clin Oncol"},{"key":"4236_CR17","unstructured":"CPIC\u00ae Guideline for Fluoropyrimidines and DPYD. https:\/\/cpicpgx.org\/guidelines\/guideline-for-fluoropyrimidines-and-dpyd\/"},{"key":"4236_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","volume":"28","author":"CATC Lunenburg","year":"2020","unstructured":"Lunenburg CATC, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM et al (2020) Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet 28:508\u2013517","journal-title":"Eur J Hum Genet"},{"key":"4236_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejca.2018.11.010","volume":"107","author":"LM Henricks","year":"2019","unstructured":"Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E et al (2019) A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. Eur J Cancer 107:60\u201367","journal-title":"Eur J Cancer"},{"key":"4236_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/tpj.2013.25","volume":"13","author":"MC Van Staveren","year":"2013","unstructured":"Van Staveren MC, Guchelaar HJ, van Kuilenburg AB, Gelderblom H, Maring JG (2013) Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J 13:389\u2013395","journal-title":"Pharmacogenomics J"},{"key":"4236_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbino J, Schellens JHM, Swen JJ et al (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharm Ther 103:210\u2013216","journal-title":"Clin Pharm Ther"},{"key":"4236_CR22","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","volume":"19","author":"LM Henricks","year":"2018","unstructured":"Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E et al (2018) DPYD genotype-guided dose individualization of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 19:1459\u20131467","journal-title":"Lancet Oncol"},{"key":"4236_CR23","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.bbadis.2016.12.010","volume":"1863","author":"ABP Van Kuilenburg","year":"2017","unstructured":"Van Kuilenburg ABP, Meijer J, Maurer D, Dobritzsch D, Meinsma R, Los M et al (2017) Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing. Biochim Biophys Acta Mol Basis Dis 1863:721\u2013730","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"4236_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00439-010-0879-3","volume":"128","author":"ABP Van Kuilenburg","year":"2010","unstructured":"Van Kuilenburg ABP, Meijer J, Mul ANMP, Meinsma R, Schmid V, Dobritzsch D et al (2010) Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 128:529\u2013538","journal-title":"Hum Genet"},{"key":"4236_CR25","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.bbadis.2016.01.009","volume":"1862","author":"ABP Van Kuilenburg","year":"2016","unstructured":"Van Kuilenburg ABP, Meijer J, Tanck MWT, Dobritzsch D, Zoetekouw L, Dekkers LL et al (2016) Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene. Biochim Biophys Acta 1862:754\u2013762","journal-title":"Biochim Biophys Acta"},{"key":"4236_CR26","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1111\/bcp.13719","volume":"84","author":"LM Henricks","year":"2018","unstructured":"Henricks LM, Jacobs BAW, Meulendijks D, Pluim D, van den Broek D, de Vries N et al (2018) Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers. Br J Clun Pharmacol 84:2761\u20132769","journal-title":"Br J Clun Pharmacol"},{"key":"4236_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/PL00008711","volume":"104","author":"AB Van Kuilenburg","year":"1999","unstructured":"Van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, Van Lenthe H et al (1999) Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 104:1\u20139","journal-title":"Hum Genet"},{"key":"4236_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ijc.10599","volume":"101","author":"ABP Van Kuilenburg","year":"2002","unstructured":"Van Kuilenburg ABP, Meinsma JR, Zoetekouw L, van Gennip AH (2002) Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1G>A mutation. Int J Cancer 101:253\u2013258","journal-title":"Int J Cancer"},{"key":"4236_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00280-009-1147-x","volume":"65","author":"A Loganayagam","year":"2010","unstructured":"Loganayagam A, Arenas-Hernandez M, Fairbanks L, Ross P, Sanderson JD, Marinaki AM (2010) The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients. Cancer Chemother Pharmacol 65:403\u2013406","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"4236_CR30","doi-asserted-by":"publisher","first-page":"e0175998","DOI":"10.1371\/journal.pone.0175998","volume":"12","author":"MC Etienne-Grimaldi","year":"2017","unstructured":"Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C et al (2017) New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS ONE 12(5):e0175998","journal-title":"PLoS ONE"},{"issue":"5","key":"4236_CR31","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41416-020-0962-z","volume":"123","author":"N Pallet","year":"2020","unstructured":"Pallet N, Hamdane S, Garinet S, Blons H, Zaanan A, Paillaud E et al (2020) A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency. Br J Cancer 123(5):811\u2013818","journal-title":"Br J Cancer"},{"key":"4236_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00439-009-0653-6","volume":"125","author":"ABP Van Kuilenburg","year":"2009","unstructured":"Van Kuilenburg ABP, Meijer J, Mul ANPM, Hennekam RCM, Hoovers JMN, de Die-Smulders CEM et al (2009) Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3). Hum Genet 125:581\u2013590","journal-title":"Hum Genet"},{"key":"4236_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/clpt.2013.69","volume":"94","author":"SM Offer","year":"2019","unstructured":"Offer SM, Lee AM, Mattison LK, Fossum NJ, Wegner RB, Diasio RB (2019) A DPYD variant (Y186C) in individuals of African ancestry is associated with reduced DOD enzyme activity. Clin Pharmacol Ther 94:158\u2013166","journal-title":"Clin Pharmacol Ther"},{"key":"4236_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1200\/JCO.2020.38.4_suppl.2","volume":"38","author":"C Kosinski","year":"2020","unstructured":"Kosinski C, Wen J, Nhan H, Chubb A, Wu S (2020) Allele frequencies of two dihydropyrimidine dehydrogenase (DPYD) risk variants, c.1905+1G>A (*2A) and c.2846A>T (D949V), in a direct-to-consumer genetic database. J Clin Oncol 38:2\u20132. https:\/\/doi.org\/10.1200\/JCO.2020.38.4_suppl.2","journal-title":"J Clin Oncol"},{"key":"4236_CR35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/gutjnl-2013-306571","volume":"64","author":"D Rosmarin","year":"2015","unstructured":"Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, Domingo E et al (2015) A candidate gene study of capecitabine-realted toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut 64:111\u2013120","journal-title":"Gut"},{"issue":"4","key":"4236_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/jpm8040045","volume":"8","author":"A Amirfallah","year":"2018","unstructured":"Amirfallah A, Kocal GC, Unal OU, Ellidokuz H, Oztop I (2018) Basbinar Y (2020) DPYD, TYMS and MTHFR genes polymorphism frequencies in a series of Turkish colorectal cancer patients. J Pers Med 8(4):45","journal-title":"J Pers Med"},{"issue":"9","key":"4236_CR37","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","volume":"74","author":"SM Offer","year":"2014","unstructured":"Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB (2014) Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res 74(9):2545\u20132554","journal-title":"Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-021-04236-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T16:15:21Z","timestamp":1617812121000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-021-04236-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["4236"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04236-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"assertion":[{"value":"5 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Raymon Vijzelaar is employed by MRC Holland that manufactures MLPA probemixes. The remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was waived by the local Ethics Committee of Vaasa Central Hospital in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent for publication was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}